Investigators at Indiana University School of Medicine have added some fresh preclinical evidence to suggest that the protein Sestrin 3 could one day play a role in treating or preventing Type 2 diabetes.
Just as Eli Lilly and Boehringer Ingelheim's new diabetes drug Jardiance hit store shelves in the U.S., cost-effectiveness watchdogs in the U.K. were considering whether to give it their blessing. The verdict as of Thursday morning? Nay.
Sales of Lipitor, the best-selling drug of all time, may be waning, but litigation over the cholesterol fighter is growing--a lot.
Insulin pumps do a better job of helping control glucose levels in people with Type 2 diabetes than multiple daily injections, according to results from a new study funded by medical device maker Medtronic.
After four years of sifting data, the FDA says it found "no clear evidence" that Daiichi Sankyo's blockbuster blood pressure drug increased the risk of heart attack. But the agency will require new safety-related data on Benicar's official label.
Scientists at Stony Brook Medicine in New York have discovered a compound that could block a protein involved in determining a person's predisposition to getting diabetes.
The FDA may not have been so keen on Boehringer Ingelheim and Eli Lilly's Type 2 diabetes drug Jardiance when it issued a complete response letter in March for problems at its future production site. That didn't stop its across-the-pond counterpart from green-lighting the drug Friday--and it won't keep it from cracking the blockbuster barrier, analysts say. But that doesn't mean getting there will be easy.
A naturally occurring molecule that mimics some of the effects of physical exercise could be used to treat insulin resistance and Type 2 diabetes, according to Canadian researchers.
With big money to be made, drugmakers have responded to the global rise in Type 2 diabetes with a host of new classes of treatments that work in different ways. And while that is generally a good thing, the full range of adverse effects of all of these new drugs can't be known until they have been on the market for awhile, and some will fare better than others, a new report states.
AstraZeneca won U.S. approval of its Bydureon pen for once-weekly treatment of Type 2 diabetes. The pen will be the first of its kind to hit the market. The prefilled, single-use pen injector delivers microspheres that house exenatide, which is slowly released for better glycemic control.